<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00884052</url>
  </required_header>
  <id_info>
    <org_study_id>Thrasher 02825-1</org_study_id>
    <nct_id>NCT00884052</nct_id>
    <nct_alias>NCT00461409</nct_alias>
  </id_info>
  <brief_title>Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures</brief_title>
  <acronym>Keppra</acronym>
  <official_title>Pharmacokinetic and Safety Trial of Intravenous Levetiracetam in the Treatment of Neonatal Seizures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Richard H. Haas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of
      Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In adults, drug clearance is less than half of the glomerular filtration rate and the drug
      half-life is 6-8 hours. Renal function in infants at birth is characterized by immature
      glomerular filtration and is only 20% that of older children. The specific esterase
      responsible for levetiracetam hydrolysis has not been identified and its expression in
      newborn infants is unknown. Depending on its activity, the expected infant total
      levetiracetam clearance will likely be between 15-45% of older populations. However, due to
      immaturity in levetiracetam clearance in infants, accumulation with multiple dosing is
      possible. Therefore the maintenance dose is reduced compared to older children according to
      the anticipated impaired clearance.

      These anticipated differences in levetiracetam clearance and volume of distribution, will
      likely result in a prolonged drug half-life of 10-30 hours in infants. This prolonged
      elimination will require longer sampling to adequately characterize levetiracetam
      pharmacodynamics in this population.

      The primary intent of the data analysis is to determine levetiracetam pharmacokinetics in
      newborn infants and predict the dosage necessary to maintain concentrations similar to those
      seen with effective therapy in other populations. Graphs of serum concentration vs. time will
      be plotted for levetiracetam for each infant. Mean serum drug concentration vs. time curves
      will also be constructed. Summary statistics (i.e., n, mean, standard deviation, minimum,
      maximum, and coefficient of variation) will be calculated for serum concentrations for each
      time point and each dose level.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug Clearance</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Half Life</measure>
    <time_frame>Day 1 and Day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Levetiracetam Treated Number of Participants With Serious Adverse Events</measure>
    <time_frame>7 Days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Seizures</condition>
  <condition>Disorder of Fetus or Newborn</condition>
  <arm_group>
    <arm_group_label>levetiracetam dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose levetiracetam</intervention_name>
    <description>20 mg/kg loading dose; 5 mg/kg daily for 7 days.</description>
    <arm_group_label>levetiracetam dose escalation</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose levetiracetam</intervention_name>
    <description>40 mg/kg IV load; 10 mg/kg/day maintenance</description>
    <arm_group_label>levetiracetam dose escalation</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns admitted to the UCSD, Children's Hospital or Sharp Mary Birch NICUs with
             seizures.

          -  Term infants (gestational age greater than or equal to 37 weeks.

          -  &gt; 2500 grams (max blood for study 6mL =3%).

          -  Postnatal age 14 days or less.

          -  Serum creatinine less than 1.2 at time of enrollment.

          -  Received loading dose of phenobarbital 20mg/kg.

          -  Are still experiencing either clinical or electroencephalographic seizures despite
             this therapy.

          -  For whom parental consent to participate in the study is obtained.

        Exclusion Criteria:

          -  Biochemical abnormality - hypoglycemia, hypocalcemia-that when treated result in
             seizure cessation.

          -  Severe hypoxic ischemic injury likely to result in imminent death

          -  The only significant exclusions that will be made in recruitment and enrollment will
             be the exclusion of infants who are judged by the attending neonatologist to be so
             critically ill that death is imminent and benefit from neonatal intensive care is very
             unlikely.

          -  No rule-based criteria, (using lab or clinical parameters) adequately capture the
             complete nature of this clinical assessment.

          -  In general any child receiving active treatment with head cooling will not be
             excluded.

          -  Mechanical ventilation and/or the use of inotropic agents to support blood pressure
             will not be exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>14 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calfornia, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Diego Medical Center / Neonatal Intensive Care Unit (NICU)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Sharpe CM, Capparelli EV, Mower A, Farrell MJ, Soldin SJ, Haas RH. A seven-day study of the pharmacokinetics of intravenous levetiracetam in neonates: marked changes in pharmacokinetics occur during the first week of life. Pediatr Res. 2012 Jul;72(1):43-9. doi: 10.1038/pr.2012.51. Epub 2012 Apr 11.</citation>
    <PMID>22495532</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 17, 2009</study_first_submitted>
  <study_first_submitted_qc>April 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2009</study_first_posted>
  <results_first_submitted>June 13, 2014</results_first_submitted>
  <results_first_submitted_qc>March 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 26, 2020</results_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Richard H. Haas</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Neonatal seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Fetal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment over 2 years from neonatal intensive care units</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Levetiracetam Low Dose</title>
          <description>Levetiracetam 20 mg/kg load followed by 5 mg/kg/day for 7 days. n=6</description>
        </group>
        <group group_id="P2">
          <title>Levetiracetam High Dose</title>
          <description>Levetiracetam 40 mg/kg load followed by 10 mg/kg/day for 7 days. n=12</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Neonates 14 days old or less. Newborns with Seizures Despite Phenobarbital Treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Levetiracetam Dose Escalation</title>
          <description>Escalation of dose after 6 patients treated to 40 mg/kg IV load and 10mg/kg/day maintenance
levetiracetam : 20 mg/kg loading dose; 5 mg/kg daily for 7 days.
levetiracetam : 40 mg/kg IV load; 10 mg/kg/day maintenance</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.44" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug Clearance</title>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>Subjects were grouped together to improve the reliability of the analysis. The publication of these results reported a grouped analysis because of the small number of subjects in the low dose group, The groups were not analyzed individually.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in both low dose and high dose arms are reported together</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Clearance</title>
          <population>Subjects were grouped together to improve the reliability of the analysis. The publication of these results reported a grouped analysis because of the small number of subjects in the low dose group, The groups were not analyzed individually.</population>
          <units>ml/min/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Levetiracetam Treated Number of Participants With Serious Adverse Events</title>
        <time_frame>7 Days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Levetiracetam Low Dose</title>
            <description>6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily
levetiracetam: 20 mg/kg loading dose; 5 mg/kg daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Levetiracetam High Dose</title>
            <description>12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day</description>
          </group>
        </group_list>
        <measure>
          <title>Levetiracetam Treated Number of Participants With Serious Adverse Events</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Drug Half Life</title>
        <time_frame>Day 1 and Day 7</time_frame>
        <population>Subjects were grouped together to improve the reliability of the analysis. The publication of these results reported a grouped analysis because of the small number of subjects in the low dose group, The groups were not analyzed individually.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants in both low dose and high dose arms are reported together</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Half Life</title>
          <population>Subjects were grouped together to improve the reliability of the analysis. The publication of these results reported a grouped analysis because of the small number of subjects in the low dose group, The groups were not analyzed individually.</population>
          <units>hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5" spread="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>7 days</time_frame>
      <desc>Mild adverse events which resolved spontaneously and were possibly related to treatment with LEV included mild sedation in 2 subjects, feeding difficulty in 3 subjects, mild apnea and bradycardia in one subject and decreased urine output responding to furosemide in one subject. In no case was LEV thought causative of an adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>There were two arms (1) Levetiracetam 20 mg/kg load followed by 5 mg/kg/day for 7 days. n=6 and (2) Levetiracetam 40 mg/kg load followed by 10 mg/kg/day for 7 days. n=12, however the data collected regarding adverse events was not recorded according to group, so all participants are reported together.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <description>A baby with a CNS developmental anomaly on high dose phenobarbital also treated with levetiracetam for seizures required intubation and ventilation for respiratory failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeding Difficulty</sub_title>
                <description>Mild adverse events which resolved spontaneously and were possibly related to treatment with LEV included feeding difficulty in 3 subjects. In no case was LEV thought causative of an adverse event.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <description>Mild adverse events which resolved spontaneously and were possibly related to treatment with LEV included mild sedation in 2 subjects. In no case was LEV thought causative of an adverse event.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Apnea and Bradycardia</sub_title>
                <description>Mild adverse events which resolved spontaneously and were possibly related to treatment with LEV included mild apnea and bradycardia in one subject . In no case was LEV thought causative of an adverse event.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Urine output</sub_title>
                <description>Mild adverse events which resolved spontaneously and were possibly related to treatment with LEV included and decreased urine output responding to furosemide in one subject. In no case was LEV thought causative of an adverse event.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sponsor and Principal Investigator</name_or_title>
      <organization>University od California San Diego</organization>
      <phone>8588226700</phone>
      <email>rhaas@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

